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CAM use among overweight and obese persons
with radiographic knee osteoarthritis
Kate L Lapane1*, Shibing Yang2, Rachel Jawahar2, Timothy McAlindon3 and Charles B Eaton4,5

Abstract
Background: Obesity is associated with knee pain and is an independent predictor of incident knee osteoarthritis
(OA); increased pain with movement often leads patients to adopt sedentary lifestyles to avoid pain. Detailed
descriptions of pain management strategies by body mass index (BMI) level among OA patients are lacking. The
objectives were to describe complementary and alternative medicine (CAM) and conventional medication use by
BMI level and identify correlates of CAM use by BMI level.
Methods: Using Osteoarthritis Initiative baseline data, 2,675 patients with radiographic tibiofemoral OA in at least
one knee were identified. Use of CAM therapies and conventional medications was determined by interviewers.
Potential correlates included SF-12, CES-D, Western Ontario and McMaster Universities Osteoarthritis Index, and
Knee injury and Osteoarthritis Outcome Score quality of life. Multinomial logistic regression models adjusting for
sociodemographic and clinical factors provided estimates of the association between BMI levels and treatment use; binary
logistic regression identified correlates of CAM use.
Results: BMI was inversely associated with CAM use (45% users had BMI ≥35 kg/m2; 54% had BMI <25 kg/m2), but
positively associated with conventional medication use (54% users had BMI ≥35 kg/m2; 35.1% had BMI <25 kg/m2).
Those with BMI ≥30 kg/m2 were less likely to use CAM alone or in combination with conventional medications when
compared to patients with BMI <25 kg/m2.
Conclusions: CAM use is common among people with knee OA but is inversely associated with BMI. Understanding
ways to further symptom management in OA among overweight and obese patients is warranted.
Keywords: Knee osteoarthritis, Obesity, Pain, Complementary and alternative medicine

Background
Obesity is an independent predictor of incident knee osteoarthritis (OA) [1]. Both weight gain and malalignment are
also associated with increased pain and functional loss [2].
OA patients with body mass index (BMI) ≥ 35 kg/m2 often
experience increased pain due to significant increases in
joint stress and load forces on the knees [3]. Obesity is a
modifiable risk factor for the development and treatment
of knee pain [4]. In two major trials [5,6], people randomized to intensive lifestyle interventions which focused on
exercise and weight loss demonstrated improvements in
pain and physical function relative to controls. Interventions including both exercise and weight loss were more
successful than those using either approach alone [7].
* Correspondence: kate.lapane@umassmed.edu
1
Department of Quantitative Health Sciences, University of Massachusetts
Medical School, Worcester, MA, USA
Full list of author information is available at the end of the article

Diffusing interventions is challenging because increased
pain with movement often leads patients to adopt sedentary lifestyles to avoid pain, which leads to more weight
gain, pain, and disability.
OA is a chronic disease with no cure so patients often
treat pain with conventional medications or therapies [8]
and complementary and alternative medicines (CAM)
[9,10]. Glucosamine [11] and acupuncture [12] do relieve
symptoms among OA patients. Obese adults are less likely
to use CAM overall [13], but detailed CAM practices
among people with higher BMI are unknown.
The Osteoarthritis Initiative (OAI) provides the opportunity to address this gap in the literature. The OAI
is a multi-center, prospective observational study which
examines the natural history of and identifies risk factors
for incidence and progression of knee OA [14]. The OAI
is a unique data source because it provides a population

© 2013 Lapane et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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Lapane et al. BMC Complementary and Alternative Medicine 2013, 13:241
http://www.biomedcentral.com/1472-6882/13/241

with radiographic confirmation of OA and detailed
assessments of knee-specific pain, quality of life, and
functioning indicators using standardized instruments.
The study purpose was twofold: 1) to describe differences in treatment approaches to manage symptoms of
knee OA by level of BMI; and 2) to evaluate the extent
to which sociodemographic and clinical correlates of
CAM use differed by BMI.

Methods
The University of Massachusetts Medical School Institutional Review Board reviewed and approved the protocol
for this study. Because publicly-available data were used for
this study, the Institutional Review Board waived the need
for documentation of informed consent from participants.
We used publicly available data from the OAI (http://
www.oai.ucsf.edu/) (#AllClinical00, V0.2.2). The OAI
began recruiting in 2004 and engaged 4,796 participants
aged 45 to 79 years. At baseline, each participant underwent 3.0 Tesla MRI examinations of the knee and
provided blood samples, and each clinical site had
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readers (trained through didactic and interactive webbased methods) assess fixed flexion knee x-rays for
osteophytes and joint space narrowing. Eligibility was
restricted to those without severe joint space narrowing
in both knees. The participants were followed annually
for the development or progression of knee OA. We included 2,679 individuals with radiographic tibiofemoral
knee OA (e.g. OARSI atlas osteophyte grade I–III) [15]
in at least one knee at baseline and excluded 4 participants
with missing height and/or weight measured using standardized methods (n = 2,675). Participants were classified
into four categories: BMI less than 25 kg/m2, BMI between 25 and less than 30 kg/m2 (overweight), BMI from
30 to less than 35 kg/m2 (obese), and BMI of at least
35 kg/m2 (severe obesity) [16].
Classification of use of CAM and conventional medications

Complementary and alternative therapies were defined
as [9]: 1) alternative medical systems (e.g. homeopathy,
acupuncture); 2) mind-body interventions (e.g. pilates,
spiritual activities, relaxation therapy); 3) manipulation

Table 1 Sociodemographic and descriptive characteristics of participants with radiographic-confirmed knee OA by BMI
level (N = 2,675)
BMI ≥ 35 kg/m2

BMI between 30 and <35 kg/m2

BMI between 25 and <30 kg/m2

BMI < 25 kg/m2

(n = 364)

(n = 804)

(n = 1,042)

(n = 465)

Percentage
Age (years): ≥ 65

27.5

39.6

48.9

49.9

Women

69.0

57.8

50.3

69.0

Race/ethnicity: White

58.8

72.7

82.7

89.3

38.7

24.3

13.3

6.5

Latino

1.1

0.8

1.8

1.7

Other

1.4

2.2

2.1

2.6

40.8

50.4

59.9

66.2

36.9

28.2

22.7

21.3

African American

Education:≥College graduate
Some college
≤ High school

22.4

21.3

17.5

12.6

Income ($):>100,000

15.6

20.1

24.3

22.4

50 k–100 k

29.9

35.8

36.2

40.0

25 k–50 k

31.4

27.9

26.7

24.0

≤ 25,000

23.1

16.2

12.8

13.7

Married/partnered

53.4

62.9

68.8

73.9

Working (for pay)

65.1

61.1

57.0

52.3

Health insurance

91.6

96.1

98.3

98.5

Insurance covers prescriptions

83.3

87.5

87.9

86.7

CES-D > 16 (Depressed)

15.9

10.1

7.2

7.5

71.7 (14.9)

70.8 (14.7)

67.7 (13.1)

60.7 (10.1)

SF-12* Mental summary

52.3 (9.5)

53.4 (8.6)

54.7 (7.5)

53.9 (7.9)

SF-12* Physical summary

42.4 (10.6)

46.8 (9.3)

48.6 (9.0)

50.9 (8.0)

Mean (standard deviation)
Weight at age 25 (kg)

*SF-12 (range: 0 to 100 with higher scores indicating better health).
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and body-based methods (e.g. massage and chiropractic);
4) energy therapies (e.g. copper bracelets); 5) topical
biologically based therapies including rubs (e.g. tiger
balm); 6) biologically based diet; or 7) biologically based
supplements (e.g. glucosamine, chondroitin). CAM use
for the past year was determined by a series of questions
including, “During the past 6 months, did you use the
following health supplements for joint pain or arthritis?”
Conventional medication use was captured in baseline
surveys as self-reported use. A four-level outcome variable
was created: CAM use only, conventional medication use
only, both, and no use.

Potential correlates

Treatment of OA is influenced by sociodemographic
indicators, overall measures of mental and physical wellbeing, and clinical indices of OA. We anticipated CAM
use to be different by age group [17], gender [18], race/
ethnicity [19,20], education [21], annual household
income, employment status, and health insurance status.
Physical and mental health status were assessed by the
12-item Medical Outcomes Study Short Form (SF-12)
[22] (range from 0 to 100, with higher scores indicating
better health status). Depression status was measured
with the CES-D Scale (≥16) [23].

Page 3 of 9

A pain score of 20 in the Western Ontario and
McMaster Universities (WOMAC) Osteoarthritis Index
(Version LK 3.1) [24,25] indicated the worst pain (range
0 to 20). Knee-related quality of life was measured by
the Knee injury and Osteoarthritis Outcome Score
(KOOS) by calculating a summary score ranging from 0
to 100 (range: 0 (extreme symptoms) to 100 (no symptoms)) [26]. The knee with worse measures was used
in the analysis. Walking ability and endurance were
measured by a 20-meter walk, averaged over two trials
[27]. The chair stand test directly assessed leg strength and
knee function and duration of time (seconds) needed to
stand up and sit down five times as quickly as possible [28].
Participants were classified by x-ray joint space narrowing as determined by OARSI atlas grade on a fixed
flexion radiograph of the knee with the worst measure.
Multiple-joint OA symptoms were measured with selfreported information at baseline: low back pain in previous
30 days, OA in hand, hip symptoms, and hip replacement.
Information on previous history of knee injury or surgery
was also collected.
Analytic approach

A multivariable multinomial logistic regression model
was developed to estimate the association between BMI
level and CAM/conventional treatment use after adjusting

Table 2 Clinical characteristics of participants with radiographic-confirmed knee OA by BMI level (N = 2,675)
BMI ≥ 35 kg/m2

BMI between 30
and <35 kg/m2

BMI between 25
and <30 kg/m2

BMI < 25 kg/m2

(n = 364)

(n = 804)

(n = 1,042)

(n = 465)

Symptoms
WOMAC*–Pain

Mean (standard deviation)
6.1 (4.7)

4.4 (4.0)

3.7 (3.6)

2.8 (3.3)

53.5 (25.1)

60.3 (22.5)

64.2 (22.5)

69.5 (21.0)

Isometric strength/chair stands (seconds)

13.1 (4.4)

12.1 (4.0)

11.6 (3.8)

10.6 (3.0)

20-meter walk (seconds)

17.5 (4.0)

16.3 (3.1)

15.5 (2.8)

15.1 (2.6)

KOOS*–QOL
Function and performance

Joint space narrowing: x-ray evidence of knee severity

Percentage

OARSI grade 0 (normal)

26.9

27.5

31.0

35.1

OARSI grade 1–2 (narrowed)

52.2

51.5

46.6

48.2

OARSI grade 3 (severe)

20.9

21.0

22.4

16.8

Bilateral knee OA

68.4

66.0

60.9

53.3

Any back pain (30 days)

66.5

56.7

56.3

59.6

Hand osteoarthritis

15.8

17.6

18.1

22.5

Hip symptoms (12 months)

30.9

24.4

23.9

21.2

Total hip replacement

0.8

2.5

1.8

1.9

History of knee injury

52.8

46.8

47.2

46.0

History of knee surgery

27.6

29.0

31.9

26.9

Multi-joint osteoarthritis

History

*WOMAC score ranges from 0 to 20, with 20 indicating worst pain. KOOS score ranges from 0 (extreme symptoms) to 100 (no symptoms).
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and chair stand test were calculated as one standard
deviation change in each variable. To determine correlates
of CAM use stratified by BMI levels, we created separate
logistic regression models for each BMI level. The outcome variable in these models was use of CAM (yes/no).

for sociodemographic and clinical characteristics. We used
a multinomial logistic regression model because the outcome variable of interest was four levels: 1) use of CAM
only; 2) use of conventional medications only; 3) use of
both; and 4) use of neither. The models produced odds
ratios (ORs) and corresponding 95% confidence intervals
(CIs). Multicollinearity among the variables of interest was
assessed and ruled out by evaluating a correlation matrix
before the modeling process and then by carefully evaluating the standard errors as new variables were introduced
into the model. Odds ratios for the KOOS- QOL scale

Results
Table 1 shows sociodemographic measures by BMI level.
Most participants with BMI ≥ 35 kg/m2 were women (69.0%)
and were younger than participants with BMI < 25 kg/m2
(27.5% over 65 years of age vs. 49.9%). Seventy-four percent

Table 3 CAM use among participants with radiographic-confirmed knee OA by BMI level (N = 2,675)
Categorya

BMI ≥ 35 kg/m2

BMI between 30
and <35 kg/m2

BMI between 25
and <30 kg/m2

BMI < 25 kg/m2

(n = 364)

(n = 804)

(n = 1,042)

(n = 465)

Percentage
Alternative medical systems

1.1

0.8

1.1

2.2

Acupuncture

0.3

0.5

0.5

1.5

Acupressure

0.3

0

0.3

0.4

0

0

0

0

Folk medicine

0

0

0

0

Homeopathy

0.3

0

0.4

0.2

Chelation therapy

Ayurveda/biofeedback/energy healing/ hypnosis/naturopathy

0.8

0.3

0.3

0.4

11.8

10.8

8.4

14.6

Yoga/Tai Chi/Chi Gong/Pilates

3.9

4.5

5.3

10.3

Relaxation therapy, meditation, breathing

3.6

4.6

2.5

3.9

Mind-body interventions

Spiritual activities
Manipulation and body-based methods

7.1

4.4

2.7

3.2

5.5

5.7

4.9

5.0

Chiropractic

4.7

4.6

4.1

3.9

Massage

2.5

1.7

1.6

1.7

Energy therapies (Copper bracelets or magnets)

5.8

3.1

3.2

3.4

Biologically based therapies: topical agent

18.1

15.1

11.9

9.7

Rubs, lotions, liniments, creams or oils(tiger balm/horse liniment)

17.6

14.8

11.7

9.7

Capsaicin

1.9

1.7

1.6

1.3

Biologically based therapies: diet

2.2

0.8

0.9

1.7

Biologically based therapies: supplements

23.4

29.2

32.9

41.3

Herbs

1.7

1.9

1.2

2.2

Vitamins/minerals (nearly every day)

5.2

6.0

6.3

7.5

Glucosamine (nearly every day)

19.8

24.5

28.8

36.6

Methylsulfonylmethane (MSM)

3.6

6.0

6.0

6.5

S-adenosylmethionine (SAMe)

0.0

0.3

0.7

0.9

Chondroitin (nearly every day)

19.0

22.1

26.5

32.5

One

28.3

32.0

33.0

35.1

Two

11.3

9.8

9.1

14.4

Three or more

5.0

4.2

3.5

4.3

Distributionb of CAM use:

a

As defined by the National Center for Complementary and Alternative Medicine;
Number of CAM use was defined on basis of the broader categories.

b
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Table 4 Conventional medication use among participants with radiographic-confirmed knee OA by BMI level (N = 2,675)
Category

BMI ≥ 35 kg/m2

BMI between 30
and <35 kg/m2

BMI between 25
and <30 kg/ m2

BMI < 25 kg/m2

(n = 364)

(n = 804)

(n = 1,042)

(n = 465)

18.1

11.4

9.7

8.8

Percentage
Acetaminophen
Any NSAIDs

35.4

26.9

24.2

23.2

Over-the-counter NSAIDs

27.8

21.4

19.7

18.1

Prescription NSAIDs

12.4

7.8

6.2

6.5

COX-2 Inhibitors

9.9

8.5

8.7

6.9

Acetaminophen or NSAIDs

45.9

34.1

29.9

28.4

Doxycycline

0.3

0.4

0.5

0.0

Narcotics

5.8

3.5

1.4

2.2

Knee injectionsa

4.7

4.5

3.4

2.6

Hyaluronic acid

1.1

1.1

1.2

0.9

Steroids

4.4

3.7

2.0

1.3

One

34.6

29.5

27.1

26.7

Two

13.5

9.1

7.9

6.9

Three or more

5.5

3.0

2.1

1.5

Distribution of conventional medications:

b

a

The sum of percentages of hyaluronic acid and steroid injections may not be equal to the total percentage of knee injections because participants may use both
hyaluronic acid and steroids, or use injections other than hyaluronic acid and steroids.
b
Number of conventional medication used was based on the first seven items in this table.

of participants with BMI < 25 kg/m2 were married
whereas 53.4% of those with BMI ≥ 35 kg/m2 were.
Sixty-six percent of participants with BMI < 25 kg/m2
were at least a college graduate whereas 41% of those
with BMI ≥ 35 kg/m2 had.
Table 2 shows clinical measures by BMI level. The
mean KOOS QOL score for participants with BMI <
25 kg/m2 was 69.5 (standard deviation: 21.0) and it was
53.5 in participants with BMI ≥ 35 kg/m2 (standard

deviation: 25.1). The mean WOMAC pain scores was
6.1 in participants with BMI ≥ 35 kg/m2 (standard deviation: 4.7) and 2.8 in participants with BMI < 25 kg/m2
(standard deviation: 3.3). Severe joint space narrowing
was 20.9% in participants with BMI ≥ 35 kg/m2 and
16.8% in participants with BMI < 25 kg/m2.
Table 3 shows specific CAM therapies stratified by
BMI level. Fifty percent of participants with BMI <
25 kg/m2 and 39.6% of participants with BMI ≥ 35 kg/m2

Figure 1 Distribution of concomitant conventional medication use among CAM users, stratified by BMI level.

Lapane et al. BMC Complementary and Alternative Medicine 2013, 13:241
http://www.biomedcentral.com/1472-6882/13/241

used one or two CAM therapies, either alone or with
conventional medication. Although more participants
with BMI < 25 kg/m2 used CAM overall relative to overweight and obese participants, differences by specific
CAM type exist. Energy therapies were more common
amongst overweight and obese participants (5.8% ≥
35 kg/m2 versus 3.4% BMI < 25 kg/m2) as were topical
therapies (18.1% ≥ 35 kg/m2 versus 9.7% BMI < 25 kg/m2).
Table 4, which shows specific conventional therapies by
BMI level, indicates the reverse is true for conventional
medications; 8.4% of participants with BMI < 25 kg/m2
and 19% of participants with BMI ≥ 35 kg/m2 reported at
least two conventional medications. Doxycycline use was
very low overall.
Figure 1 shows CAM use and types of concurrent
conventional medication use by BMI level. The most
commonly used concurrent conventional therapies amongst
all BMI groups was acetaminophen and/or non-steroidal
anti-inflammatory agents (NSAIDs) which were over-thecounter or prescription.
Table 5 shows the association between CAM and conventional treatment use and BMI level. Both participants
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with BMI between 30 and 35 kg/m2 and participants
with BMI between 25 and 30 kg/m2 reported using
CAM with conventional medications less often than
participants with BMI < 25 kg/m2 (adjusted odds ratio
(AOR): 0.38, 95% CI: 0.20-0.73 for participants with BMI
between 30 and 35 kg/m2; AOR: 0.35, 95% CI: 0.19-0.65
for participants with BMI between 25 and 30 kg/m2).
Table 6 shows correlates of any CAM use by BMI
level. Participants with BMI ≥ 35 kg/m2 and over 65 years
of age were more likely to use CAM than younger
participants (AOR: 2.79, 95% CI: 1.53-5.09). Black
persons with BMI between 25 and 30 kg/m2 were less
likely to report CAM use compared to white persons
(AOR: 0.36, 95% CI: 0.23-0.58). Among persons with
BMI of 25 to 30 and 30 to 35 kg/m2, having a college
degree or higher was associated with CAM use, relative
to a high school education or less (AOR: 1.71 and 1.84,
respectively).

Discussion
Persons with BMI levels of at least 25 kg/m2 had greater
prevalence of severe joint space narrowing, greater pain,

Table 5 Association between BMI level and treatment approaches among people with knee OA
Treatment use

CAM only

Conventional medications only

Both

Odds ratios
(95% Confidence intervals)
BMI ≥ 35 kg/m2 versus referent group BMI <25 kg/m2
Crude
Socio-demographic adjusted†
Socio-demographic and clinical characteristic adjusted††

0.48

2.51

1.38

(0.31–0.73)

(1.55–4.07)

(0.94–2.04)

0.50

1.69

1.16

(0.28–0.91)

(0.81–3.53)

(0.65–2.09)

0.47

1.13

0.55

(0.24–0.92)

(0.47–2.70)

(0.27–1.12)

0.70

1.71

0.94

(0.50–0.98)

(1.09–2.68)

(0.66–1.34)

0.71

1.29

0.71

(0.43–1.17)

(0.65–2.57)

(0.41–1.22)

0.59

0.84

0.38

(0.34–1.04)

(0.37–1.88)

(0.20–0.73)

BMI between 30 and <35 kg/m2 versus referent group BMI <25 kg/m2
Crude
Socio-demographic adjusted†
Socio-demographic and clinical characteristic adjusted††

BMI between 25 and <30 kg/m2 versus referent group BMI <25 kg/m2
Crude
Socio-demographic adjusted†
Socio-demographic and clinical characteristic adjusted††
†

0.68

1.29

0.77

(0.50–0.94)

(0.83–2.01)

(0.55–1.09)

0.49

0.78

0.52

(0.31–0.80)

(0.39–1.55)

(0.31–0.88)

0.47

0.75

0.35

(0.28–0.79)

(0.35–1.63)

(0.19–0.65)

Adjusted for age, gender, race/ethnicity, marital status, education, employment status, income, health insurance, prescription drug insurance, and depression.
Also adjusted for physical and mental health component scores, KOOS quality of life, WOMAC pain scale, weight at 25 years of age, hip replacement, history of
knee surgery, complaints of pain in multiple joints, OARSI severity scale, isometric strength/chair stands, and 20-meter walk.

††
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Table 6 Correlates of CAM use among participants with radiographic-confirmed knee OA by BMI level
BMI ≥ 35 kg/m2

BMI between 30
and <35 kg/m2

BMI between 25
and <30 kg/m2

BMI < 25 kg/m2

(n = 364)

(n = 804)

(n = 1,042)

(n = 465)

a

Odds ratios (95% Confidence intervals)
Age ≥ 65 years

2.79 (1.53-5.09)

1.29 (0.89-1.86)

1.01 (0.73-1.39)

1.22 (0.72-2.06)

Women

1.85 (1.08-3.15)

1.56 (1.11-2.17)

1.66 (1.25-2.21)

3.27 (2.03-5.27)

Race/ethnicity
Black

0.87 (0.51-1.48)

0.84 (0.57-1.25)

0.36 (0.23-0.58)

1.06 (0.42-2.71)

Latino

1.04 (0.13-8.13)

1.73 (0.24-12.34)

0.98 (0.33-2.97)

1.53 (0.30-7.68)

Other

0.20 (0.02-2.14)

1.69 (0.57-5.00)

1.48 (0.54-4.07)

2.35 (0.63-8.81)

1.0

1.0

1.0

1.0

≥College graduate

0.96 (0.49-1.87)

1.84 (1.20-2.82)

1.71 (1.14-2.56)

1.58 (0.80-3.13)

Some college

1.00 (0.52-1.91)

1.54 (0.97-2.43)

1.43 (0.91-2.24)

1.37 (0.63-2.96)

1.0

1.0

1.0

1.0

Employment status

2.21 (1.26-3.88)

1.08 (0.75-1.55)

0.83 (0.61-1.13)

1.66 (1.01-2.73)

Depression

1.28 (0.66-2.50)

0.89 (0.52-1.52)

0.95 (0.55-1.64)

0.34 (0.14-0.81)

b

KOOS–QOL

0.70 (0.53-0.91)

0.55 (0.45-0.66)

0.66 (0.57-0.78)

0.62 (0.48-0.80)

Multi-joint osteoarthritis

1.36 (0.79-2.33)

1.64 (1.17-2.30)

1.25 (0.94-1.68)

1.96 (1.24-3.11)

Non-hispanic white
Education

High school or less

Isometric strength/chair stands (seconds)
OARSIc Grade 3 (severe)
Grade 1–2 (narrowed)
Grade 0 (normal)
a

b

0.92 (0.71-1.19)

0.78 (0.66-0.93)

1.06 (0.91-1.23)

0.95 (0.74-1.21)

1.87 (0.92-3.79)

1.28 (0.79-2.06)

1.60 (1.07-2.39)

2.49 (1.26-4.91)

1.27 (0.73-2.22)

1.08 (0.74-1.56)

1.15 (0.84-1.58)

1.17 (0.73-1.86)

1.0

1.0

1.0

1.0

b

c

Models stratified by obesity levels. Odds ratios are per one standard deviation change in KOOS-QOL scale and chair stand test. X-ray evidence of joint
space narrowing.

and reduced quality of life relative to persons with
BMI < 25 kg/m2. Despite a greater disease burden among
persons with BMI ≥ 25 kg/m2, we observed less CAM
use and greater conventional medication use relative to
those with BMI < 25 kg/m2. Our study was consistent
with general population studies in that use of individual
CAM modalities were less common in those with higher
BMI levels, albeit differences were modest [13]. Chiropractic use did not differ substantially by levels of BMI,
which was not consistent with studies showing less
chiropractic use among obese persons [29]. Considering
all individual CAM modalities, CAM use, either alone or
in conjunction with conventional medications, was less
common among persons with higher BMI levels. We
acknowledge that the clinical relevance of some of the
observed differences is unclear.
The correlates of CAM use differed by BMI level for
some, but not all factors. Women were more likely to
report use of CAM for knee OA than men and quality
of life was inversely associated with CAM use. Age of at
least 65 years was associated with CAM use only among
those with BMI ≥ 35 kg/m2. Black participants tended to
have lower odds of CAM use relative to white participants
among those with BMI between 25 and <30 kg/m2. This

association was not evident among other BMI levels. Our
finding that black participants had reduced odds of use of
CAM therapies than white participants was consistent
with some previous studies [30]. The reasons for racial
differences in CAM use are likely multifactorial, including
different access to health care and socioeconomic positioning. In our study, black participants had less favorable
socioeconomic positioning relative to white participants.
Residual confounding from socioeconomic status may
partially explain the inverse association. The reasons
for inconsistent association between race and CAM use
across BMI levels are unclear. Among persons with
BMI < 25 kg/m2, depression was inversely associated with
CAM use. We are unable to evaluate the extent to which
these findings are consistent with the literature because, to
our knowledge, no BMI level-specific correlates of CAM
use have been published.
Given there is no cure for OA, the clinical implications
of these findings must be considered. The use of CAM
to slow disease progression is not supported by research,
yet symptom relief among OA patients has been
reported with glucosamine [11] and acupuncture [12].
Obesity is a modifiable risk factor for the development
and treatment of knee pain [4]. Indeed, evidence from
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trials [5-7] suggests that intensive exercise and weight
loss interventions result in improved pain and physical
function measures. However, the beneficial effects of
weight loss may be challenged by joint damage and
chronic pain from OA, which cause muscle atrophy,
decreased mobility, poor balance, and eventual physical
disability [4]. Some researchers have suggested that
adoption of weight loss strategies may be hampered by
pain, and that intensive treatment of pain resulting from
knee OA may improve exercise capacity and quality of
life [4].
The reasons why use of the treatment options is less
among persons with higher BMI levels are likely multifactorial, and may include differences in patient preference, knowledge, and access to CAM. As the OAI did
not collect such information, we were unable to explore
the extent to which these factors explained observed
differences. Reports show CAM users in general pursue
generally healthy lifestyles [31], but use of CAM for
weight loss remains relatively low [32]. The latter finding
may suggest that persons with higher BMI levels may be
reluctant to use CAM in general, rather than reluctant
to use CAM specifically for OA symptom relief.
This study has several important limitations to consider. The data shown are cross-sectional. The temporal
sequence of symptoms and treatment cannot be determined from this design. Data regarding symptoms and
treatment are based on self-report and may have introduced bias. However, the information regarding conventional medications and CAM therapies are based on
either a 30-day or 6-month recall. We believe this type
of misclassification is likely minimal and non-differential
with respect to BMI levels. Thus, if any distortions were
introduced, they would have attenuated the observed
associations. We are unable to comment on the extent
to which patterns of CAM use by BMI levels indicate
overuse of CAM by persons with lower BMI level or
underuse of CAM by persons with higher BMI levels.

Conclusion
Our study suggests that despite increased burden of disease, overweight and obese patients with radiographicallyconfirmed knee OA are using CAM therapies less often
than those with lower BMI levels, but use of conventional
medications are more common in overweight and obese
patients. Overweight and obese adults may be less likely
to use effective CAM therapies relative to persons with
BMI < 25 mg/k2. Further research is needed to improve
our understanding of the role of CAM in the treatment of
knee OA among overweight and obese persons.
Abbreviations
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